Start Date
March 1, 2023
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2028
Dostarlimab
First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
University of Miami Sylvester Comprehensive Cancer Center, Miami
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Miami
OTHER